One-Time CRISPR Gene Therapy Offers New Hope for Severe Genetic Diseases
Advances in CRISPR-based treatments are turning gene editing into a potential one-time therapy for certain inherited disorders, although access, cost and long-term safety remain major challenges.
Scientists and biotechnology companies are increasingly developing one-time CRISPR gene therapies designed to address diseases at their genetic source rather than requiring lifelong treatment. One prominent example is Casgevy, a CRISPR/Cas9 therapy approved for certain patients with severe sickle cell disease and transfusion-dependent beta thalassemia. In 2026, the treatment is becoming available at specialized centers in additional countries, including Qatar.
CRISPR works by allowing scientists to make targeted changes to DNA. In the case of Casgevy, a patient’s blood stem cells are collected and genetically edited outside the body before being returned after specialized treatment. The edited cells can then produce increased levels of fetal hemoglobin, helping reduce the effects of sickle cell disease or the need for regular transfusions in eligible patients with beta thalassemia.
Early clinical results have been encouraging. Sidra Medicine reported that approximately 97% of patients in the pivotal sickle-cell trial were free from vaso-occlusive crises for at least one year, while virtually all patients with transfusion-dependent beta thalassemia in the cited trial became transfusion-independent. These results illustrate why researchers view gene editing as a potentially transformative approach, although continued monitoring is essential to understand how durable the benefits remain over many years.
The technology is also expanding beyond blood disorders. Companies are developing in-vivo CRISPR therapies, in which gene editing components are delivered directly into the body rather than requiring cells to be removed and modified outside the patient. For example, Intellia Therapeutics began a rolling FDA submission for lonvo-z, a one-time CRISPR treatment being developed for hereditary angioedema.
Despite the excitement, these treatments are not simple or universally available cures. Gene-editing procedures can require complex preparation, specialized medical facilities and careful patient selection. Scientists must also continue studying long-term safety and unintended genetic changes. The bigger breakthrough, therefore, is not that CRISPR has solved genetic disease, but that medicine is increasingly moving toward one-time treatments designed to modify the underlying biology of a disease rather than repeatedly treating its symptoms.
